- Cancer Types
Information about risk, prevention, screening, symptoms, diagnosis, treatment, and support for all cancers Cancer A to Z - Cancer Treatment
Cancer Treatment
Information about cancer treatment, including surgery, chemotherapy, radiation therapy, clinical trials, proton therapy, complementary medicine, and cutting edge technologies.
- Risk and Prevention
- Cancer Drugs
- Support
Support
Ways for cancer patients and caregivers to cope with cancer, side effects, nutrition, general cancer support issues, grief/end of life issues, and shared survivor's experiences.
- Healthcare Professionals
- Clinical Trials
My Patient Treatment Binder
OncoLink Blogs
What's My Cancer Risk?
OncoPilot: Navigating Your Cancer Journey
Community Events Calendar
OncoLink eNews
Abramson Cancer Center
Sunday, June 1 , 2008
OncoLink reporters provide in-depth coverage of scientific presentations from the 44th Annual ASCO Meeting.
|
A Phase II multicenter, randomized trial to compare anastrazole plus gefitinib with anastrazole plus placebo in postmenopausal women with hormone receptor-positive (HR+) metastatic breast cancer (MBC)
Presenter: M. CristofanilliPresenter's Affiliation: MD Anderson Cancer CenterType of Session: ScientificBackground It is well known that hormonal receptor status is an important prognostic factor in metastatic breast cancer patients and has... |
|
|
A randomized phase III trial of four cisplatin (CIS) containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group (GOG) study
Presenter: B. J. MonkPresenter's Affiliation: University of California, Irvine, Orange, CAType of Session: ScientificBackground Cervical cancer represents the third most common gynecologic malignancy in the United States. Although... |
|
|
A randomized phase III trial of four cisplatin (CIS)- containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group (GOG) study
A randomized phase III trial of four cisplatin (CIS)- containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: A Gynecologic Oncology Group (GOG) study Several studies have demonstrated varying degrees of benefit... |
|
|
Adjuvant ovarian suppression combined with tamoxifen or anastrazole, alone or in combination with zoledronic acid, in premenopausal women with endocrine-responsive, stage I and II breast cancer: First efficacy results from ABCSG
Presenter: M. GnantPresenter's Affiliation: Medical University of ViennaType of Session: ScientificBackground In hormone receptor-positive breast cancers, growth of the tumor is stimulated by estrogens. Decreasing the production of... |
|
|
FLEX: A randomized,multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
Presenter: R. PirkerPresenter's Affiliation: Medical University of Vienna, Vienna, AustriaType of Session: PlenaryBackground Lung cancer represents the most common cause of cancer death in both men and women in the United States. Non-small... |
|
|
FLEX: A randomized,multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC)
FLEX: A randomized,multicenter, phase III study of cetuximab in combination with cisplatin/ vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC) Epidermal growth factor (EGFR) is... |
|
|
KRAS Status and Efficacy in the First –Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI with or without Cetuximab: The Crystal Experience
KRAS Status and Efficacy in the First –Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI with or without Cetuximab: The Crystal Experience Cetuximab is a targeted therapy agent that blocks epidermal... |
|
|
KRAS Status and Efficacy in the First –Line Treatment of Patients with Metastatic Colorectal Cancer (mCRC) Treated with FOLFIRI with or without Cetuximab: The Crystal Experience
Presenter: Van Cutsem E. Presenter's Affiliation: University Hospital Gasthuisberg, Leuven, Belgium Type of Session: Plenary Background Cetuximab is a chimeric antibody which blocks epidermal growth factor (EGF) signaling by binding to the EGF... |
|
|
Radiotherapy versus carboplatin for Stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214)
Presenter: R. T. OliverPresenter's Affiliation: St. Bartholomew’s Hospital, London, United KingdomType of Session: PlenaryBackground Seminonas are the most common subtype of testicular cancers, accounting for about 40% of cases. Stage I... |
|
|
Radiotherapy versus carboplatin for Stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214)
Radiotherapy versus carboplatin for Stage I seminoma: Updated analysis of the MRC/EORTC randomized trial (ISRCTN27163214) Seminoma (the most common type of testicular cancer) has traditionally been treated with orchiectomy followed by radiation... |
|
|
Randomised, double-blind, placebo controlled, phase III study of bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO
Presenter: David Miles, MDPresenter's Affiliation: Mount Vernon Cancer Center, UKType of Session: ScientificBackground Bevacizumab (BV) is a monoclonal antibody to VEGF that inhibits angiogenenesis, and therefore prevents tumor growth. It... |
|
|
Randomised, double-blind, placebo controlled, phase III study of bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO
Randomised, double-blind, placebo controlled, phase III study of bevacizumab (BV) with docetaxel (D) or docetaxel with placebo (PL) as first line therapy for patients with locally recurrent or metastatic breast cancer (mBC): AVADO Bevacizumab is a... |
|
|
Randomized Trial of Standard Versus Higher Dose Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Cancer (SCLC) Complete Responders (CR): Primary End Point Analysis (PCI99-01, EORTC 22003-08004, RTOG 0212)
Presenter: Le Pechoux C.Presenter's Affiliation: Institute Gustav Roussy, Villejuif, FranceType of Session: ScientificBackground The use of prophylactic cranial irradiation (PCI) in patients with limited stage small cell lung cancer (SCLC) has... |
|
|
Randomized Trial of Standard Versus Higher Dose Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Cancer (SCLC) Complete Responders (CR): Primary End Point Analysis (PCI99-01, EORTC 22003-08004, RTOG 0212)
Randomized Trial of Standard Versus Higher Dose Prophylactic Cranial Irradiation (PCI) in Limited Stage Small Cell Lung Cancer (SCLC) Complete Responders (CR): Primary End Point Analysis (PCI99-01, EORTC 22003-08004, RTOG 0212) The use of... |
|
|
Sentinel Lymph Node Biopsy Improves Survival Among SEER Patients with Melanoma
Presenter: Gimotty P. Presenter's Affiliation: University of Pennsylvania Type of Session: Scientific Background Regional lymph node metastases increase the risk of melanoma-specific death. Sentinel lymph node biopsy (SLNB) provides... |
|
|
SO124: A Randomized Phase III Trial Comparing Irinotecan/Cisplatin (IP) with Etoposide/Cisplatin (EP) in Patients (pts) with Previously Untreated Extensive Stage Small Cell Lung Cancer (E-SCLC)
Presenter: Natale R.B.Presenter's Affiliation: Cedar Sinai Cancer Center, Los Angeles, CaliforniaType of Session: ScientificBackground The most widely accepted standard of care for small call lung cancer (SCLC) for the past 20 years has been... |
|
|
SO124: A Randomized Phase III Trial Comparing Irinotecan/Cisplatin (IP) with Etoposide/Cisplatin (EP) in Patients (pts) with Previously Untreated Extensive Stage Small Cell Lung Cancer (E-SCLC)
SO124: A Randomized Phase III Trial Comparing Irinotecan/Cisplatin (IP) with Etoposide/Cisplatin (EP) in Patients (pts) with Previously Untreated Extensive Stage Small Cell Lung Cancer (E-SCLC) The combination of etoposide and cisplatin (EP) is the... |
|
|
Vaginal brachytherapy versus external beam pelvic radiotherapy for high-intermediate risk endometrial cancer: Results of the randomized PORTEC-2 trial
Presenter: R.A. NoutPresenter's Affiliation: Leiden University Medical Center, Leiden, NetherlandsType of Session: ScientificBackground Endometrial carcinoma represents the most common gynecologic malignancy in the United States, and the second... |
Cancer Types
Bone Cancer
Brain Tumors
Breast Cancer
Carcinoid Tumors
Endocrine System Cancers
Gastrointestinal Cancers
Gynecologic Cancers
Head and Neck Cancers
Leukemia
Lung Cancers
Lymphomas
Myelomas
Pediatric Cancers
Penile Cancer
Prostate Cancer
Sarcomas
Skin Cancers
Testicular Cancer
Thyroid Cancer
Urinary Tract Cancers
OncoLink Vet
Cancer Treatment
Biologic Therapy
Bone Marrow Transplants
Chemotherapy
Clinical Trials
Complementary Medicine
Gene Therapy
General Treatment Concerns
Hormone Therapy
PDT Center
Proton Therapy
Radiation Oncology
Surgical Oncology
Targeted Therapies
Vaccine Therapies
Cancer Support
Caregivers
Hospice Care and Bereavement
Nutrition and Cancer
Sexuality & Fertility
Side Effects
Support
Survivorship
Exercise and Cancer
Cancer Resources
Cancer News
OncoLink University
Nurses' Notes
Conferences
Newly Diagnosed Patients
Causes and Prevention
Legal and Financial Information for Patients
LGBT Resources
NCI Resources
Global Resources
Cancer Resource List
Resources for Young Adults
OncoLink Media Library
OncoLink TV
Book, Music and Video Reviews
Ask the Experts
Brown Bag Chat
Tracy's Corner
About OncoLink
About OncoLink
Giving to OncoLink
Contact Information
Usage Policy
Editorial Board
How to Partner with OncoLink
Link to OncoLink
Mission Statement
